

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

Sector Healthcare Value Fund

Class Y USD Shares (ISIN: IE00BMXR2498)

A sub-fund of Sector Capital Funds Plc. Regulated by the Central Bank of Ireland.

Manufacturer and Management Company: Sector Fund Services AS. Regulated by The Financial Supervisory Authority of Norway.

Investment Manager: Sector Gamma AS. Regulated by The Financial Supervisory Authority of Norway.

www.sectorgamma.no | Call +47 23 01 29 00 for more information.

Release date: 13/02/2024

What is this product?

Type: Long Only UCITS Fund

Objective: The investment objective of Sector Healthcare Value Fund (the "Fund") is to achieve attractive long-term investment returns relative to the MSCI Daily TR World Net Health Care USD (the "Index"). The Fund is actively managed, which means that the Investment Manager is actively making investment decisions for the Fund. The Index is a capitalisation weighted index that monitors the performance of health care stocks from around the world. The Fund may invest in equities and financial instruments that are not part of the Index. The Investment Manager intends to pursue the Fund's investment objective by implementing a long only strategy consisting of investment in equity and equity related securities issued by companies in the global healthcare sector. The global healthcare sector includes, but is not limited to, companies involved in pharmaceuticals, biotechnology, medical technology, and health care services. The basic thesis of the Investment Manager is to buy equities that in their opinion are undervalued by the respective market. The Investment Manager will seek to identify and exploit such mis-pricings through fundamental analysis. The Fund may invest up to 10% of its assets in other collective investment schemes; including exchange traded funds which themselves invest in the global healthcare sector. The Fund may also invest in equity based derivative contracts such as swaps, forwards, contracts for differences, convertibles, and rights.


SFDR Classification: The Fund is classified as an Article 8 financial product.

Intended Retail Investor: Investments in the Fund may be suitable for investors with a long-term investment horizon.

Product Term: Required minimum holding period: None. This product has no maturity date.

What are the risks and what could I get in return?

Risk Indicator:



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 4 out of 7, which is a medium risk class. This rates the potential losses from future performance at a medium level, and poor market conditions could impact the Fund's capacity to pay you.

Be aware of currency risk. You may receive payments in a different currency from your home state currency, and as such the final return you will get depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

This product does not include any protection from future market performance so you could lose some or all of your investment. If the Fund is not able to pay out, you could lose your entire investment.

KEY INFORMATION DOCUMENT Page 1 of 3



What are the risks and what could I get in return? (continued)

Recommended holding period: 5 years Example investment: USD 10 000

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product over the last 5 years. The stress scenario shows what you might get back in extreme market circumstances, and it does not take into account the situation where we are not able to pay you

Performance Scenarios	If you exit after 1 year	If you exit after 3 years	If you exit after 5 years
Reference period for scenario calculations	Jan 2023 - Dec 2023	Jan 2021 - Dec 2023	Jan 2019 - Dec 2023
Stress scenario			
What you might get back after costs	USD 3 775	USD 5 200	USD 4 198
Average return each year	-62.25%	-19.58%	-15.94%
Unfavourable scenario			
What you might get back after costs	USD 8 954	USD 9 110	USD 9 675
Average return each year	-10.46%	-3.06%	-0.66%
Moderate scenario			
What you might get back after costs	USD 10 817	USD 12 632	USD 14 748
Average return each year	8.17%	8.10%	8.08%
Favourable scenario			
What you might get back after costs	USD 13 027	USD 17 463	USD 22 412
Average return each year	30.27%	20.42%	17.52%

The scenarios shown illustrate how your investment could perform. You can compare them with the scenarios of other products. The scenarios presented are an estimate of future performance based on evidence from the past on how the value of this investment varies and are not an exact indicator. What you get will vary depending on how the market performs and how long you keep the investment/product.

The figures shown include all the costs of the product itself but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What happens if the Fund is unable to pay out?

The Fund is not protected by any investor compensation or guarantee scheme. The manufacturer of this Fund has no obligations to "pay out". Investors may, however, suffer loss if the Fund is unable to pay out, and you may lose all of your investment.

What are the costs?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

The Reduction in Yield ("RIY") shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs. The amounts shown here are the cumulative costs of the product itself, for three different holding periods.

The figures are estimates and may change in the future. You should note that these costs are paid by the Fund whereas the return that you may receive will depend on the Fund's share price performance. There is no direct link between the Fund's share price and the costs that it pays.

We have assumed:

- In the first year you would get back the amount that you invested (0% annual return).
- For the 3 and 5 years holding periods we have assumed the product performs as shown in the moderate scenario.
- USD 10 000 is invested.

Table 1: Costs over time

Scenarios	If you exit after 1 year	If you exit after 3 years	If you exit after 5 years*
Total costs	USD 90	USD 300	USD 540
Impact on return (RIY) per year	0.88%	0.98%	1.06%

^{*} Recommended holding period



What are the costs? (continued)

Table 2: Composition of costs

One-off costs		
Entry costs Exit costs Ongoing costs taken each year	None None	The Fund does not charge any entry og exit fees when you subscribe or redeem your investment.
Management fees and other administrative or operating costs	0.64%	Costs related to running the Fund, including but not limited to management fee to the Investment Manager, fees to the Administrator, Depositary, Auditors, Legal advisors and Directors.
Transaction costs	0.24%	Portfolio transaction costs are the costs of buying and selling underlying investments in the Fund.
Incidental costs taken under spec	ial conditio	ns
Performance fees	15.00%	The Fund charges 15% on the Fund's relative performance to the Index (when the Fund performs better than the Index). The performance fee becomes payable only when you redeem your investment or in a situation where the Fund closes down. The performance fee may be payable even if the absolute return on your investment is zero or negative.

How long should I hold it and can I take my money out early?

This product has no required minimum holding period. It is designed for long term investors. You may sell your shares in the Fund on any day which is a regular business day in Dublin, New York and Oslo. No fees or penalties are payable to the Fund on sale of your investment, but you may be required to pay fees or commissions to any person arranging the sale on your behalf.

How can I complain?

If you have any complaints about the Investment Manager, you may lodge your complaint by writing to Sector Gamma AS at P.O. Box 462 Sentrum, 0105 Oslo, Norway or by email to info@sectorgamma.no. Further information on the complaints procedure can be found on Sector Asset Management's website: www.sector.no. If you have a complaint about a person who is advising on, or selling, the product you should pursue that complaint with the relevant person in the first instance.

Other relevant information

Depending on how you buy and sell these shares you may incur other costs, including broker commission, platform fees and Stamp Duty. The distributor will provide you with additional documents where necessary. Further documentation, including the Fund's Prospectus, Supplement, annual and semi-annual reports and regulatory disclosures, is available on the Investment Manager's website at www.sectorgamma.no. The cost, performance and risk calculations included in this Key Information Document follow the methodology prescribed by EU rules. The Fund is a sub-fund of Sector Capital Funds Plc, which is authorised in Ireland and regulated by the Central Bank of Ireland.

Past performance

Information on past performance is available through the following link: Past performance

Previous performance scenarios

Information on previous performance scenarios is available through the following link: Previous performance scenarios

Representative share class

Class Y USD has been chosen as the representative share class for Class Y EUR (ISIN: IE00BMXR2506) and Class Y GBP (ISIN: IE00BMXR2613). Further information on share classes is available in the Fund's Supplement.

KEY INFORMATION DOCUMENT Page 3 of 3